Eindrückliche Verbesserung des Überlebens beim metastasierten HER2-low-Mammakarzinom – Etablierung einer neuen Subgruppe?

Burris HA et al (2011) Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 29:398–405 Fehrenbacher L et al (2018) Abstract GS1-02: NSABP B‑47 (NRG oncology): Phase III randomized trial comparing adjuvant chemotherapy with adriamycin (A) and cyclophosphamide (C) → weekly paclitaxel (WP), or docetaxel (T) and C with or without a year of trastuzumab (H) in women with node-positive or high-risk node-negative invasive breast cancer (IBC) expressing HER2 staining intensity of IHC 1+ or 2+ with negative FISH (HER2-Low IBC). Cancer Res 78:GS1–2 Modi S et al (2022) Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 387:9–20 Bardia A et al (2021) Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med 384:1529–1541 Pervan M et al (2021) Deutliche Verbesserung des Gesamtüberlebens durch Sacituzumab-Govitecan beim metastasierten tripelnegativen Mammakarzinom. Onkologe 27:1131–1136 Ogitani Y et al (2016) DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T‑DM1. Clin Cancer Res 22:5097–5108